European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis: Report from Italy

Medical Mycology

Volumn 40, Issue 5, 2002, Pages 507-517

  Viviani, Maria Anna ^a   Antinori, S ^a   Cogliati, M ^a   Esposto, M C ^a   Pinsi, G ^a   Casari, S ^a   Bergamasco, A ^a   De Santis, M L ^a   Ghirga, P ^a   Bonaccorso, C ^a   Jacchetti, G ^a   Niero, F ^a   Ammassari, A ^a   Morace, G ^a   Uberti Foppa, C ^a   Ossi, C ^a   Montagna, M T ^a   Angarano, G ^a   Farina, C ^a   Maggiolo, F ^a   Moroni, M ^a   Pierdomenico, S ^a   Michelone, G ^a   Cavanna, C ^a   Viti, F ^a   Carli, T ^a   Barchiesi, F ^a   Agrappi, C ^a   Mena, M ^a   Giola, M ^a   Tinelli, M ^a   Ceraminiello, A ^a   Codeluppi, M ^a   Casolari, C ^a   Foresti, S ^a   Bramati, S ^a   Ruggieri, A ^a   Caggese, L ^a   Astolfi, A ^a   Bonora, S ^a   Scotton, P G ^a   Rigoli, R ^a   Angioni, G ^a   Meneghetti, F ^a   Di Perri, G ^a   more..

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cryptococcosis; Cryptococcus neoformans sero genotypes; Epidemiology; Italy

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AGGLUTINATION TEST; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; FEMALE; FUNGAL STRAIN; FUNGICIDE RESISTANCE; FUNGUS ISOLATION; GENOTYPE; HEALTH CARE ORGANIZATION; HEALTH SURVEY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRID; IN VITRO STUDY; INCIDENCE; INTERMETHOD COMPARISON; ITALY; MAJOR CLINICAL STUDY; MALE; MICROBIAL SENSITIVITY TEST; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDY; QUESTIONNAIRE; REPRODUCIBILITY; SEROTYPING;

CRYPTOCOCCUS NEOFORMANS VAR. NEOFORMANS; FILOBASIDIELLA NEOFORMANS; FUNGI; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036809349     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/mmy.40.5.507.517     Document Type: Article

References (38)

1. Kwon-Chung KJ, Bennett JE. Cryptococcosis. In: Kwon-Chung KJ, Bennett JE, eds. Medical Mycology. Philadelphia, PA: Lea & Febiger, 1992: 430-431.
2. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: separate varietal state for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999; 37: 838-840.
3. Bennett JE, Kwon-Chung KJ, Howard DH. Epidemiologic differences among serotypes of Cryptococcus neoformans. Am J Epidemiol 1977; 105: 582-586.
4. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21: 28-34.
5. Dromer F, Mathoulin S, Dupont B, et al. Epidemiology of cryptococcosis in France: a 9 year survey (1985-1993). Clin Infect Dis 1996; 23: 82-90.
6. Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179: 449-454.
7. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988; 157: 624-628.
8. Newton JA Jr, Tasker SA, Bone WD, et al. Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection. AIDS 1995; 9: 1286-1287.
9. Costagliola D. Clinical Epidemiology Group from CISIH. Trends in incidence of clinical manifestations of HIV infection and antiretroviral prescriptions in French university hospitals [abstract 182]. In: 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998.
10. Chen S, Sorrel T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin Infect Dis 2000; 31: 499-508.
11. Viviani MA, Swinne D, Kouzmanov A, et al. Survey of cryptococcosis in Europe. The ECMM working group report [abstract WG-02]. Abstracts of the 6th Congress of the European Confederation of Medical Mycology, Barcelona 9-11 November 2000. Rev Iberoam Micol 2000; 17: S115.
12. Barnett JA, Payne RW, Yarrow D. Yeasts: Characteristics and Identification, 2nd edn. Cambridge: Cambridge University Press, 1990.
13. Viviani MA, Esposto MC, Cogliati M, et al. Isolation of a Cryptococcus neoformans serotype A MATa strain from the Italian environment. Med Mycol 2001; 39: 383-386.
14. Viviani MA, Wen H, Roverselli A, et al. Identification by polymerase chain reaction fingerprinting of Cryptococcus neoformans serotype AD. J Med Vet Mycol 1997; 35: 355-360.
15. Cogliati M, Allaria M, Liberi G, et al. Sequence analysis and ploidy determination of Cryptococcus neoformans var. neoformans. J Mycol Méd 2000; 10: 171-176.
16. Cogliati M, Esposto MC, Clarke DL, et al. Origin of Cryptococcus neoformans var. neoformans diploid strains. J Clin Microbiol 2001; 39: 3889-3894.
17. Lengeler KB, Cox GM, Heitman J. Serotype AD strains of Cryptococcus neoformans are diploid or aneuploid and are heterozygous at the mating-type locus. Infect Immun 2001; 69: 115-122.
18. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M-27A. Vilanova, PA: National Committee for Clinical Laboratory Standards, 1997/17.
19. Ghannoum M, Ibrahim AS, Fu Y, et al. Susceptibility testing of Cryptococcus neoformans: A microdilution technique. J Clin Microbiol 1992; 30: 2881-2886.
20. Esposto MC, Cogliati M, Tortarano AM, et al. The pH effect on the in vitro susceptibility of Cryptococcus neoformans to flucytosine (5FC): correlation of in vitro data with clinical outcome [abstract PO29]. 5th International Conference on Cryptococcus and Cryptococcosis, Adelaide 3-7 March 2002.
21. Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual frame work and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Clin Infect Dis 1997; 24: 235-247.
22. Cuenca-Estrella M, Diaz-Guerra TM, Lellado E, et al. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur J Clin Microbiol Infect Dis 2001; 20: 276-279.
23. Tortorano AM, Viviani MA, Rigoni AL, et al. Prevalence of serotype D in Cryptococcus neoformans isolates from HIV positive and HIV negative patients in Italy. Mycoses 1997; 40: 297-302.
24. White M, Cirrincione C, Blevins A, et al. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992; 165: 960-963.
25. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997. AIDS 1998; 12: 1931-1933.
26. Martinez E, Garcia-Viejo MA, Marcos MA, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14: 2615-2617.
27. Woods ML II, Lacginley R, Eisen DP, et al. HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection. AIDS 1998; 12: 1491-1494.
28. Manfredi R, Pieri F, Pileri SA, et al. The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review. Mycopathologia 999; 148: 73-78.
29. Backo M, Tomalty L, Wobeser W. The role of cryptococcal latex antigen tests. Clin Microbiol News 2001; 23 (8): 64-66.
30. Tintelnot K, Adler S, Bergmann F, et al. Case reports. Disseminated cryptococcosis without cryptococcal antigen detection. Mycoses 2000; 43: 203-207.
31. Steembergen JN, Casadevall A. Prevalence of Cryptococcus neoformans var. neoformans (serotype D) and Cryptococcus neoformans var grubii (serotype A) isolates in New York City. J Clin Microbiol 2000; 38: 1974-1976.
32. Cogliati M, Esposto MC, Liberi G, et al. Molecular epidemiology of cryptococcosis [abstract L-29]. Abstract of the 6th Congress of the European Confederation of Medical Mycoology, 9-11 November 2000 (Barcelona, Spain). Rev Iberoam Micol 2000; 17: S116
33. Boekout T, Theelen B, Diaz M, et al. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 2001; 147: 891-907.
34. Naka W, Masuda M, Konohana A, et al. Primary cutaneous cryptococcosis and Cryptococcus neoformans serotype D. Clin Exp Dermatol 1995; 20: 221-225.
35. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-548.
36. Pfaller MA, Zhang J, Messer SA, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. AAC 1999; 43: 169-171.
37. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. AAC 1998; 42: 471-472.
38. Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 1975; 21: 113-130.